星瑙灵对症状性颅内动脉狭窄患者的认知功能保护作用

目的 探讨星瑙灵对症状性颅内动脉狭窄患者的认知功能保护作用。方法 选择本院2017年4月-2019年4月收治的88例症状性颅内动脉狭窄患者,按治疗方式分为对照组与研究组,每组各44例,对照组采用传统治疗方法,研究组在对照组基础上加用星瑙灵治疗,2组均持续治疗3个月,使用神经功能缺损评分量表(NIHSS)、神经心理功能评估量表(MMSE、MoCA)对患者神经功能及认知功能进行评估; 收集患者血清炎症因子水平。结果 研究组总有效率(91.83%)高于对照组( 69.39%)(P<0.05)。研究组炎症因子水平优于对照组(P<0.05)。对照组简单计算测验、空间工作记忆测验、抽象思维能力测验和延迟回忆能力得分较研究组显著降低(P均<0.05)。结论 星瑙灵可能通过改善症状性颅内动脉狭窄患者的慢性炎症水平来发挥认知功能保护作用。

Seniovita plays a protective role in cognitive function of patients with symptomatic intracranial artery stenosis

ObjectiveTo investigate the protective effect of cognitive function of Seniovita on patients with symptomatic intracranial arterial stenosis.Methods 88 cases of patients with symptomatic intracranial artery stenosis in our hospital from April 2017 to April 2019 were selected, they were divided into control group and research group, 44 patients in each group, and the control group was treated with traditional treatments, the research group was treated with Seniovita on the basis of treatments of control group. Therapy was continuous for three months, National Institutes of Health Stroke Scale(NIHSS)、 Mini-Mental State Examination(MMSE)and Montreal cognitive assessment scale(MocA)were used to evaluate patients' neurologic function and cognitive function. Plasma inflammatory factor levels were collected.Results The total effective rate in the research group was 91.83%,while it was 69.39% in the control group(P<0.05). Inflammatory factor levels in the research group were better than those in the control group(P<0.05). The scores of the control group on simple calculation test, spatial working memory test, abstract thinking test and delayed recall test were significantly lower than those of the experimental group(P<0.05).Conclusion Seniovita might play a protective role in cognitive function by improving the chronic inflammatory levels in patients with symptomatic intracranial artery stenosis.